FDA.reportPublic FDA data

mepolizumab 40 MG in 0.4 ML Prefilled Syringe

RxCUI
2596444
RxNorm name
mepolizumab 40 MG in 0.4 ML Prefilled Syringe
Display name
mepolizumab 40 MG in 0.4 ML Prefilled Syringe
Full name
mepolizumab 40 MG in 0.4 ML Prefilled Syringe
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:30

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125526Nucalamepolizumab351(a)Rx2026-10-01
761122Nucalamepolizumab351(a)Rx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
fefb887c-e4ac-431e-8893-e9d1a5a63feamepolizumab 40 MG in 0.4 ML Prefilled Syringe [PSN] · 0.4 ML mepolizumab 100 MG/ML Prefilled Syringe [SCD] · mepolizumab 40 MG per 0.4 ML Prefilled Syringe [SY]324These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab) for injection, for subcutaneous use NUCALA (mepolizumab) injection, for subcutaneous use Initial U.S. Approval: 201520250806